The study of effects of Probiotic lactobacilli in Preventing Major Complications in patients of Liver Cirrhosis.

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2010/091/001321

Enrollment

Registered

2010-11-19

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Probiotic lactobacilli: 2 Billion CFU/cap Twice daily Control Intervention1: Placebo: One Capsule twice daily

Eligibility

Inclusion criteria

Inclusion criteria: Age: 30 to 50 years Sex: both Patient with sonographically confirmed diagnosis of cirrhosis Patients with liver cirrhosis with the history of major complication of cirrhosis (including variceal bleeding, encephalopathy and spontaneous bacterial peritonitis) Evidence for portal hypertension

Exclusion criteria

Exclusion criteria: Patients with alcoholic cirrhosis who still consume alcohol Patients having risk factor of small intestinal bacterial overgrowth other than cirrhosis - diabetes mellitus, history of abdominal surgery, immunomodulator drugs Patients with active or recent G.I. bleeding (within prior 7 days) Patients with advanced hepatocellular carcinoma, renal failure and portal vein thrombosis

Design outcomes

Primary

Measure	Time frame
Incidence of complications of liver cirrhosis, during the treatment periodTimepoint: From beginning to end of the study	—

Secondary

Measure	Time frame
DeathTimepoint: From beginning to end of the study;Hospital admissions due to cirrhosis complicationsTimepoint: From beginning to end of the study;Liver function testsTimepoint: Visit1, Visit2 and Visit3;Renal Function testsTimepoint: Visit1, Visit2 and Visit3;Serum ammoniaTimepoint: Visit 1, visit 2 and visit3	—

Countries

India

Contacts

Public ContactDr Pardeshi M L

narayanburte@yahoo.com02026126010

Outcome results